

Integrative Management of Pain, Oral Symptoms, Nutritional Risk, and Medication-Related Problems in Advanced Chronic Disease

Peter Novak^{1*}, Sophie Dubois², Thomas Müller³, Anna Weber⁴, Erik Johansson⁵

¹*Department of Palliative Medicine and Integrative Care, Charles University, Prague, Czech Republic.*

²*Department of Clinical Pharmacy and Palliative Care, Utrecht University, Utrecht, Netherlands.*

³*Department of Palliative Care and Oral Medicine, University of Vienna, Vienna, Austria.*

⁴*Department of Nursing and Nutritional Risk, University of Cologne, Cologne, Germany.*

⁵*Department of Palliative Medicine and Medication Management, Uppsala University, Uppsala, Sweden.*

Abstract

Patients with advanced chronic disease frequently experience pain, oral symptoms, nutritional problems, and complex medication regimens at the same time, yet these domains are commonly assessed and managed through separate clinical pathways. This integrative clinical review examined evidence published from 2017–2026 concerning the burden, interaction, assessment, and management of these domains in palliative and supportive care. Five targeted literature searches and supplementary evidence verification yielded 73 records or reports. After removal of four duplicates, 69 unique records underwent eligibility assessment; 30 clinical evidence units were retained for synthesis, supplemented by four methodological and reporting references. Evidence was heterogeneous in design, population, setting, and outcome definition and therefore was integrated without de novo quantitative pooling. Pain and oral morbidity were consistently important sources of symptom burden, while nutritional risk encompassed intake-limiting symptoms, cachexia-related concerns, psychological distress, and eating-related burden. Polypharmacy and potentially inappropriate medication use were frequent in advanced illness, although evidence for clinical benefits beyond reduction in medication burden remained variable. The strongest cross-domain evidence concerned relationships between oral symptoms and eating or feeding, whereas direct evidence connecting analgesic treatment with oral outcomes or medication burden with nutritional deterioration was less developed. Integrated management is therefore best understood as coordinated reassessment across distinct domains rather than as a single composite burden construct. Clinical integration should remain sensitive to patient goals, stage of illness, treatment burden, professional roles, and the strength of evidence supporting each proposed interaction.

Keywords: Palliative care, Pain management, Oral symptoms, Nutritional risk, Polypharmacy, Deprescribing

Introduction

Palliative and supportive care increasingly addresses a combination of symptoms, functional losses, treatment burdens, and patient priorities rather than a single dominant complaint. Ambulatory palliative-care evidence demonstrates that multidimensional symptom management can improve several patient-reported outcomes, although effects differ across individual symptoms and models of care [1, 2].

Oral morbidity constitutes a separate source of burden. Nutritional care is similarly heterogeneous. Randomized trials in incurable solid cancer encompass different nutritional interventions, endpoints, and disease stages, limiting any assumption that a single nutritional strategy has uniform clinical value [3-5].

Medication burden introduces a further layer of complexity. Deprescribing studies in life-limiting conditions generally demonstrate that medication counts or potentially inappropriate medications can be reduced, while effects on symptoms, quality of life, healthcare use, and survival remain less consistent [6].

Corresponding author: Peter Novak

Address: Department of Palliative Medicine and Integrative Care, Charles University, Prague, Czech Republic.

E-mail: ✉ peter.novak@cuni.cz

Received: 02 October 2025; **Revised:** 07 December 2025;

Accepted: 20 December 2025

How to Cite This Article: Novak P, Dubois S, Müller T, Weber A, Johansson E. Integrative Management of Pain, Oral Symptoms, Nutritional Risk, and Medication-Related Problems in Advanced Chronic Disease. *J Integr Nurs Palliat Care*. 2025;6(2):394-404. <https://doi.org/10.51847/wosLuqPHIC>

The interaction among these domains is clinically plausible but unevenly supported. This review therefore preserves each domain analytically, examines evidence for their intersections, and distinguishes directly observed relationships from clinically reasonable but under-tested integrative hypotheses [7].

Review purpose

The review examined what evidence published from 2017–2026 establishes, contests, or leaves unresolved about four clinically important domains in advanced chronic disease: pain burden, oral symptom burden, nutritional risk, and medication-related problems. It also examined evidence concerning pain treatment and oral effects, oral symptoms and nutritional intake, medication burden and nutrition, symptom clustering, patient goals, and the roles of nursing, pharmacy, dental, and nutritional professionals.

The primary unit of inclusion was a peer-reviewed clinical evidence report contributing extractable findings to at least one of these domains or their interaction. Evidence was interpreted with attention to study design, care setting, population, professional role, temporal context, alternative explanations, and the difference between association and causation.

Materials and Methods

An integrative clinical-review design was used because the review question required simultaneous consideration of systematic reviews, randomized trials, observational studies, qualitative evidence, clinical guidance, consensus research, and professional-practice studies. Integrative review methodology permits evidence with different epistemic and methodological functions to be synthesized while retaining differences in design and evidentiary strength [8, 9].

The review did not attempt a new meta-analysis. Existing pooled estimates were used only when reported by an eligible systematic review or meta-analysis. Primary studies were retained at study level and interpreted according to their actual design. Evidence was organized by clinical domain, cross-domain interaction, professional contribution, and patient-centered context.

Search strategy

Search and selection were reported using transparent record-identification principles consistent with current systematic-review reporting guidance [10, 11]. Searches were executed on 16 September 2026 through a PubMed-targeted search interface, supplemented by exact-title, DOI, citation-chain, and connected-report verification.

Five search families were used: advanced or palliative illness combined with pain; oral health, xerostomia, swallowing or oral symptoms; nutrition, cachexia, appetite or eating-related distress; medication burden, polypharmacy, deprescribing or pharmacist involvement; and symptom clustering, patient goals, nursing assessment or integrated care. The publication window was restricted to 2017–2026 during eligibility assessment. Journal quartile was not used to determine whether a clinical evidence unit was eligible for review inclusion.

The targeted searches returned 58 records, and supplementary verification identified 15 additional potentially relevant reports, yielding 73 records or reports before deduplication. Search-interface output was used for this executed review; it was not represented as a native MEDLINE database export.

Eligibility and evidence selection

Eligible reports examined adults with advanced cancer, other life-limiting illness, palliative-care needs, or closely aligned supportive-care contexts and addressed at least one locked clinical or professional domain. Reviews, trials, cohort studies, cross-sectional research, qualitative studies, consensus research, guidance, and implementation studies could be included when their findings were directly relevant. Protocols without completed findings, reports outside the publication window, weakly aligned populations, and records without extractable evidence for the review question were excluded.

Four duplicate reports were identified across the search families, leaving 69 unique records for eligibility assessment. Thirty-nine records were excluded: two were outside the publication window, one was a protocol without completed findings, ten had insufficient alignment with advanced or palliative illness, thirteen did not directly address a locked clinical or professional domain, eight were commentaries or practice discussions without sufficiently extractable results, two were overlapping companion reports for which a more directly informative report was retained, and three lacked adequate report-level information for evidence extraction without inference. The resulting clinical review corpus contained 30 evidence units. Four additional methodological references were retained for review design, reporting, appraisal, and synthesis procedures. The 30 clinical evidence units and the 34-item reference list are therefore distinct quantities.

The executed selection pathway is summarized in **Figure 1**.




Figure 1. Executed search and evidence-selection pathway for the integrative review of pain, oral symptoms, nutritional risk, and medication-related problems

Evidence evaluation

Evidence was evaluated according to study design rather than journal prestige. Systematic reviews were examined using critical-domain principles consistent with AMSTAR 2, including protocol or question clarity, search adequacy, study selection, risk-of-bias assessment, synthesis methods, and interpretation of heterogeneity [12]. No summed quality score was created.

Randomized trials were considered according to randomization, deviations from intended intervention, missing data, outcome measurement, and selective reporting. Observational studies were evaluated for selection, confounding, temporality, outcome measurement, and missingness. Qualitative evidence was interpreted according to sampling, analytic transparency, credibility, and transferability. Delphi evidence was treated as consensus evidence rather than outcome-effectiveness evidence. Where accessible information was insufficient for a confident appraisal judgment, uncertainty was retained rather than converted into a presumed low-risk designation.

Data extraction and integrative synthesis

Data extraction captured study design, setting, population, serious-illness context, professional groups, sample size where reported, focal constructs, intervention or exposure, comparison where applicable, measurements, mechanisms, temporal design, main findings, contradictory or null findings, alternative explanations, stated limitations, applicability boundaries, and potential exhibit relevance.

Heterogeneous evidence was synthesized using structured grouping principles compatible with synthesis-without-meta-analysis reporting [13, 14]. Evidence was first grouped by pain, oral symptoms, nutrition, medication burden, and professional contribution. Cross-domain evidence was then examined for direct relationships, such as oral status and feeding, or indirect relationships inferred from adjacent literatures. Direct evidence, interpretation, and new integrative synthesis remained distinct throughout the review.

Results and Discussion

The final clinical corpus contained 30 evidence units. Ten were evidence syntheses, including systematic reviews, meta-analyses, mixed-method reviews, network meta-analysis, or narrative synthesis. The remaining evidence included one clinical practice guideline, one international Delphi study, two randomized or cluster-randomized

trials, and sixteen observational, qualitative, secondary-analysis, pilot, pharmacist-intervention, or other prospective clinical studies.

The evidence distribution was uneven across domains. Pain and oral symptoms had substantial review-level literature. Nutrition research included systematic evidence, observational work, symptom-focused analyses, and pilot supportive-care interventions. Medication evidence extended from polypharmacy and potentially inappropriate medication studies to deprescribing reviews, consensus recommendations, trajectory analyses, and pharmacist-led interventions. Cross-domain relationships were less consistently studied than the individual domains themselves.

Study populations were dominated by advanced cancer and specialist or supportive palliative-care settings. This concentration strengthens applicability to oncology-oriented palliative care while reducing certainty about transfer to all forms of advanced chronic disease. Study designs, symptom instruments, medication definitions, nutritional endpoints, follow-up periods, and professional-care models also varied materially.

The methodological profile of the evidence corpus is summarized in **Table 1**.

Table 1. Methodological profile and analytical contribution of the included clinical evidence

Evidence unit type	Principal clinical function in this review	Typical population/setting represented	Main inferential strength	Main limitation for integrative interpretation
Systematic reviews and meta-analyses	Establish domain burden, intervention landscape, and consistency of prior evidence	Predominantly advanced cancer and palliative/supportive care	Broad evidence coverage and, where appropriate, pooled estimates	Heterogeneity in interventions, measures, and included populations
Network meta-analysis	Compare treatment strategies within cancer pain	Adults with cancer pain	Comparative synthesis across multiple interventions	Depends on network comparability and trial-level assumptions
Clinical practice guidance	Define evidence-informed approaches to cancer-pain management	Adult oncology and palliative care	Clinically organized recommendations	Recommendation strength does not substitute for primary comparative evidence
Randomized and cluster-randomized trials	Test structured supportive or nurse-led interventions	Advanced cancer	Stronger causal inference for tested interventions and endpoints	Model-specific findings may not transfer to other service configurations
Prospective and longitudinal cohorts	Describe symptom trajectories, clusters, changing goals, and treatment patterns	Advanced cancer and specialist palliative care	Temporal information and real-world clinical relevance	Residual confounding and attrition
Cross-sectional and secondary analyses	Examine associations among symptoms, function, oral status, medication burden, or distress	Advanced cancer and palliative populations	Detailed domain-specific association data	Limited temporal and causal inference
Qualitative evidence	Characterize lived consequences of xerostomia and treatment or eating burden	Specialist palliative care	Patient-centered depth and contextual interpretation	Limited statistical generalizability
Delphi consensus	Define areas of professional agreement in deprescribing	International end-of-life-care experts	Structured consensus across professional expertise	Consensus does not establish patient-outcome benefit
Pharmacist-led and other pilot implementation studies	Examine feasibility and clinical implementation of medication review or supportive care	Specialist palliative and outpatient services	Practice-level operational insight	Small samples and limited comparative effectiveness evidence

Pain burden

Cancer pain remains clinically heterogeneous in mechanism, severity, temporal pattern, treatment response, and relationship to other symptoms. European guidance supports individualized management according to pain characteristics, disease context, previous exposure, treatment goals, and adverse-effect burden [15]. Such guidance provides a clinical structure for management but cannot determine the best regimen for every patient. Recent prospective evidence also shows wide variation in pain intensity and opioid-related risk among people with advanced cancer [16, 17]. This variation argues against interpreting advanced disease as synonymous with a uniform level of pain burden.

Pain also appears within broader symptom contexts. Longitudinal palliative-care data in pancreatic cancer demonstrate concurrent pain and appetite-related problems across care episodes [18]. These observations support cross-domain assessment but do not establish that pain causes appetite loss or nutritional deterioration. Disease progression, treatment toxicity, inflammation, mood, gastrointestinal symptoms, and medication effects may contribute simultaneously.

Oral symptom burden

Oral symptoms include xerostomia, oral pain, candidiasis, mucosal disorders, dental problems, swallowing-related difficulties, and impaired oral function. A recent systematic review of palliative-care clinical practice guidelines found substantial variation in the quality and content of recommendations, indicating that common clinical recognition has not produced a uniformly strong guidance base [19].

Patient accounts illustrate why xerostomia deserves attention beyond oral discomfort. Qualitative evidence describes interference with eating, drinking, speech, social interaction, and daily comfort [20]. These consequences can become particularly important when patients already have low appetite, fatigue, dysphagia, or treatment-related restrictions.

Evidence for oral-hygiene interventions is developing but remains comparatively small. A mixed-methods systematic review identified potential roles for oral hygiene in symptom management while emphasizing limitations in study number, heterogeneity, and intervention specification [21]. Oral assessment therefore requires clinical attention without assuming that any single oral-care protocol has established superiority.

The relationship between oral health and feeding is more directly supported. In advanced cancer, poorer oral health has been associated with judgments concerning the advisability of oral feeding [22]. Separately, patients with advanced disease identify dry mouth as affecting eating, swallowing, taste, speech, and sleep [23]. These findings connect oral status to functional and nutritional experience, while the cross-sectional nature of much of this evidence prevents simple causal attribution.

Table 2 summarizes the evidence distinctions that must be preserved when pain and oral symptoms are interpreted together.

Table 2. Evidence distinctions across pain burden and oral symptom burden

Analytical unit	What the evidence establishes	Clinically relevant interaction	Important competing explanation	Interpretation boundary
Cancer pain	Pain varies in severity, mechanism, treatment response, and opioid exposure	Severe or persistent pain can increase overall symptom and treatment burden	Disease progression, psychological distress, and other symptoms	Pain burden alone does not establish nutritional or oral consequences
Analgesic management	Treatment must be individualized to clinical context	Medication selection may alter overall symptom experience and treatment burden	Baseline comorbidity, concurrent therapies, hydration, and disease effects	Guideline recommendations do not quantify oral adverse effects for every regimen
Xerostomia	Dry mouth can impair comfort, speech, taste, eating, and swallowing	May make oral intake more difficult or unpleasant	Dehydration, mouth breathing, disease, radiotherapy, infection, and other medications	Patient-reported impact does not establish a single causal mechanism
Oral disease and hygiene	Oral disorders are common, and oral care may assist symptom control	Oral condition can influence feeding feasibility and comfort	Performance status and systemic illness can influence both oral care and feeding	Association with feeding does not prove that oral disease alone determines intake
Oral-functional burden	Oral symptoms can affect activities essential to nutrition and quality of life	Connects local symptoms with broader supportive-care needs	Fatigue, nausea, cachexia, mood, and swallowing impairment	Functional interaction should remain multidimensional

Nutritional risk

Nutritional risk in advanced disease extends beyond body weight or caloric intake. Multicentre evidence suggests that patients with advanced cancer and greater nutrition-impact symptom burden can have correspondingly greater need for multimodal supportive care [24].

Nutrition-impact symptoms also intersect with psychological experience. Associations between such symptoms and depression have been reported in advanced cancer [25]. Depression may influence appetite and self-care, while progressive disease, inflammation, functional loss, symptom burden, and reduced intake may contribute to both nutritional and psychological deterioration.

Eating-related distress introduces a patient- and family-centered dimension. Review literature describes how inability to eat can carry meanings related to caregiving, normality, hope, social participation, and perceived decline [26]. Nutritional management therefore includes communication about what is physiologically achievable as well as attention to symptom relief and the emotional consequences of changing intake.

Prospective observational evidence indicates that nutrition-impact symptoms and eating-related distress can change during involvement of palliative-care teams [27]. Because these studies lack randomized comparison, observed improvement cannot be attributed exclusively to team involvement. Pilot work integrating supportive and nutritional care nevertheless demonstrates the feasibility of earlier coordinated approaches in selected high-risk cancer populations [28].

Medication-related problems

Medication-related problems in advanced illness include polypharmacy, potentially inappropriate medications, treatment duplication, adverse effects, drug–drug interactions, administration burden, preventive therapies with delayed benefit, and symptom-control drugs whose value may change with disease trajectory. Deprescribing is therefore best considered a structured reassessment of indication, anticipated benefit, burden, risk, prognosis, and patient goals.

An international Delphi process developed consensus recommendations for medication deprescribing in the last phase of life [29]. Consensus provides useful professional guidance, particularly where randomized evidence is sparse, while remaining distinct from evidence that deprescribing improves a particular clinical outcome.

Potentially inappropriate medication use can be substantial in older people with advanced cancer. A retrospective palliative-care cohort applying STOPPFrail criteria found a high prevalence of at least one potentially inappropriate medication [30]. The finding supports systematic medication review in appropriately selected patients, but prevalence from a single service should not be generalized to every palliative population.

Polypharmacy itself is also associated with greater symptom burden and poorer quality-of-life indicators in advanced illness [31]. Causal interpretation remains difficult. Medication burden may therefore be a contributor, a marker of illness complexity, or both.

Pain treatment and oral side effects

Analgesic therapy and oral symptoms intersect clinically, but the direct evidence base is less mature than the separate literatures on cancer pain and oral morbidity. Opioids and other symptom-control medications may contribute to dry mouth, nausea, sedation, constipation, altered intake, or treatment burden in individual patients, yet the reviewed evidence does not justify assigning xerostomia or poor oral intake primarily to analgesic exposure.

The stronger evidence supports parallel assessment. Pain management should be reviewed when new oral or nutritional symptoms emerge, while oral causes, hydration, local pathology, disease progression, concurrent medications, and treatment history are assessed simultaneously. This prevents medication effects from being overlooked without turning a plausible adverse-effect pathway into an assumed mechanism.

The distinction is especially important because pain may itself limit eating, sleep, activity, and self-care, whereas analgesia can improve those functions even when treatment introduces adverse effects. Clinical review therefore requires an individualized balance between symptom benefit and treatment burden rather than automatic dose reduction based solely on the presence of oral symptoms.

Oral symptoms and nutritional intake

The oral–nutrition interface is one of the better-supported cross-domain relationships in this review. Xerostomia can make chewing, swallowing, taste, and sustained oral intake more difficult [23]. Qualitative evidence further indicates that patients may alter food texture, fluid use, meal timing, conversation, and social participation in response to severe oral dryness [20].

Oral-health assessment provides complementary information. Associations between poorer oral health and reduced advisability of oral feeding in advanced cancer suggest that oral status can become clinically relevant to decisions about safe and tolerable intake [22]. These relationships remain embedded within overall performance status, swallowing function, disease progression, fatigue, and cognitive state.

Nutritional risk should consequently be assessed through both systemic and local pathways. The integrative task is to identify which contributors are potentially modifiable and which reflect the underlying disease trajectory.

Medication burden and nutrition

Evidence directly linking polypharmacy to nutritional deterioration in palliative care is comparatively limited. Existing studies more clearly establish medication burden, potentially inappropriate prescribing, nutrition-impact symptoms, and eating-related distress as important but partly separate clinical concerns. Integration at this point should therefore remain conditional.

Medication review may still be clinically relevant when appetite loss, nausea, dry mouth, sedation, constipation, dysphagia, or difficulty managing complex administration schedules contributes to reduced intake. The direction of effect can vary: some medications worsen symptoms, others relieve symptoms that otherwise prevent eating, and preventive therapies may add administration burden without meaningful near-term benefit.

Specialist pharmacist involvement provides a practical route for examining this balance. A pharmacist-led outpatient pilot demonstrated that opioid deprescribing can be implemented in carefully selected patients, although the population and clinical circumstances limit direct extrapolation to terminal palliative-care settings [32]. Medication decisions therefore require a clear therapeutic indication and an explicit account of what symptom or function may improve or worsen after dose reduction.

Longitudinal medication data from a palliative-care unit further show that medication profiles change across the course of an admission, with preventive medicines more commonly discontinued while drugs serving immediate symptom-control functions are maintained or increased [33]. Such trajectories are consistent with a shift toward near-term goals but should not be interpreted as evidence that any observed discontinuation pattern is universally optimal.

The resulting relationship between medication burden and nutrition is therefore best represented as a set of conditional pathways: medication effects may influence appetite, oral comfort, alertness, gastrointestinal function, or administration burden; nutritional decline may alter the tolerability or value of existing medications; and both domains are shaped by prognosis, functional status, patient goals, and the reason each medication is being used.

Symptom clustering and functional impact

Symptoms in advanced illness rarely remain isolated. Longitudinal evidence in advanced cancer demonstrates that symptom clusters can change over time and that their prognostic relevance depends on the particular symptoms grouped together [7]. For this review, clustering is therefore useful as evidence of co-occurrence and shared functional burden, not as justification for collapsing pain, oral symptoms, nutritional risk, and medication problems into a single score.

Functional impact may arise through several routes. Pain can restrict activity and self-care; oral symptoms can impair speaking, swallowing, and eating; nutrition-impact symptoms may contribute to fatigue and distress; and complex treatment regimens may add administration burden. The same observed functional decline may consequently have several plausible explanations.

Supportive-care interventions also act within this wider symptom field. Nurse-led models have been tested in advanced cancer, but intervention components and outcomes differ between studies [34]. Meta-analytic evidence likewise suggests benefits for selected outcomes while retaining substantial heterogeneity in intervention design and care setting [35]. Multisymptom improvement should therefore be attributed to the intervention actually tested rather than to an assumed universal integrated-care effect.

Patient goals and treatment burden

Clinical appropriateness changes as patients' priorities, prognosis, functional capacity, and tolerance of treatment change. Longitudinal evidence indicates that goals of care are not necessarily stable during the final years of advanced cancer [36]. A preference expressed at one stage should not automatically be treated as a permanent decision rule.

Treatment burden is especially relevant when therapeutic routines compete with comfort, eating, sleep, mobility, communication, or time with family. Eating-related distress may also carry social and emotional meanings beyond nutritional adequacy [26]. Medication review, nutrition planning, and symptom management therefore require attention to what the patient currently values, not only what can technically be treated.

Deprescribing recommendations developed through international consensus similarly emphasize that medication continuation should reflect anticipated benefit, burden, prognosis, and goals rather than medication count alone [29]. Goal-concordant care may lead to simplification in some situations and preservation of apparently burdensome treatment in others when that treatment provides immediate symptom relief or supports valued function.

Nursing assessment

Nurses often occupy the clinical position from which changes across several domains first become visible: worsening pain, reduced oral intake, xerostomia, swallowing difficulty, medication-administration problems, sedation, constipation, declining function, or caregiver concern. The value of nursing assessment therefore lies partly in repeated observation across time rather than in isolated screening.

Randomized evidence supports testing structured nurse-led supportive-care models in advanced cancer [34], while systematic review and meta-analysis show that nurse-led palliative interventions constitute a heterogeneous group rather than one standardized treatment [35]. Their effects depend on intervention content, timing, follow-up, professional integration, and the outcomes selected.

Important null evidence must also remain visible. The CONNECT cluster randomized trial did not demonstrate uniform improvement across its principal patient outcomes despite implementing a structured oncology nurse-led primary palliative-care intervention [37]. Nursing integration should consequently be understood as a clinically important care function whose effectiveness depends on model design and implementation rather than as an intervention guaranteed to improve every outcome.

Pharmacy contribution

Pharmacy input becomes particularly relevant when symptom-control therapy, chronic preventive medication, polypharmacy, and changing prognosis coexist. Pharmacists can identify potentially inappropriate medications, therapeutic duplication, administration problems, adverse-effect possibilities, and opportunities for simplification while preserving medicines that remain important for symptom relief.

Observed palliative-care medication trajectories show that preventive therapies are often discontinued as illness advances while symptom-directed medicines remain clinically prominent [33]. Pharmacist-led interventions have also demonstrated that deprescribing recommendations can be generated and implemented within specialist palliative-care practice [38]. These findings establish feasibility and professional contribution more securely than they establish downstream effects on survival, function, or quality of life.

Available deprescribing tools and guidance differ in purpose and population, and no single instrument can be assumed to resolve every medication decision [39]. Pharmacist contribution is therefore strongest when structured medication review is combined with clinical indication, prognosis, patient goals, symptom response, and input from the wider team.

Dental and nutritional contributions

Dental and oral-health assessment addresses problems that may otherwise be interpreted only as generalized deterioration. Evidence connecting oral status with oral feeding reinforces the importance of identifying local and potentially modifiable contributors [22].

Nutritional assessment serves a different but complementary function. Nutrition-impact symptoms, appetite loss, cachexia-related changes, psychological distress, and eating-related burden cannot be inferred from body weight alone [24]. Nutritional care therefore requires attention to symptom causes, functional capacity, achievable goals, and the distinction between potentially reversible intake barriers and progressive metabolic change.

Evidence for multidisciplinary interaction is stronger for individual component problems than for a fully validated integrated service model. Dental and nutritional contributions should therefore remain identifiable within team-based care rather than being absorbed into an unspecified multidisciplinary intervention.

Integrated management architecture

The evidence supports an integrated management approach based on coordinated reassessment of distinct domains. Pain, oral symptoms, nutritional risk, and medication-related problems should first be characterized separately because each has its own measurements, evidence base, mechanisms, and treatment implications. Integration begins after those distinctions are preserved.

The strongest direct interaction in the reviewed evidence concerns oral function and eating. Other clinically plausible pathways—particularly medication-related effects on nutrition and analgesic effects on oral symptoms—remain less directly established.

A practical architecture therefore requires repeated movement between domain assessment, interaction testing, professional response, and patient-goal review. Proposed relationships should be acted on as hypotheses to evaluate clinically rather than as predetermined causal explanations.

The resulting synthesis is shown in **Figure 2**.




Figure 2. Evidence-bounded integration of pain, oral symptoms, nutritional risk, medication burden, and professional response in advanced chronic disease

The reviewed evidence supports integration at the level of clinical reasoning more strongly than at the level of a single validated integrated intervention. Pain, oral symptoms, nutritional risk, and medication-related problems each have identifiable evidence bases, yet the strength of evidence connecting them differs.

This unevenness matters. Treating one observed association as the dominant causal explanation risks overlooking other modifiable contributors. Integration therefore requires structured differentiation before coordination. Professional roles show a similar pattern. Nursing, pharmacy, dental, and nutritional contributions are individually defensible, but evidence does not establish that adding every discipline produces a predictable incremental outcome in every setting.

Conclusion

Pain, oral symptoms, nutritional risk, and medication-related problems frequently coexist in advanced chronic disease, but they should not be treated as one undifferentiated burden. The most defensible approach is to assess each domain separately, identify supported interactions, test plausible contributors against alternative explanations, and coordinate professional responses around the patient's current goals and functional priorities. Evidence is strongest for several individual domains and for the connection between oral function and eating, while direct evidence for some medication–nutrition and treatment–oral pathways remains limited. Integrated management is therefore supported as a structured process of coordinated reassessment, provided that clinical decisions preserve domain-specific evidence, uncertainty, and the changing priorities of advanced illness.

Acknowledgments: None

Conflict of interest: None

Financial support: None

Ethics statement: None

References

- Shah R, Everitt R, Hince D, Kissane D, Michael N. Ambulatory palliative care and cancer symptom control: a systematic review and meta-analysis. *BMJ Support Palliat Care*. 2025;15(4):411-22. doi:10.1136/spcare-2024-005152

2. Imkamp MSV, Theunissen M, Viechtbauer W, van Kuijk SMJ, van den Beuken-van Everdingen MHJ. Shifting views on cancer pain management: a systematic review and network meta-analysis. *J Pain Symptom Manage.* 2024;68(3):223-36. doi:10.1016/j.jpainsymman.2024.05.022
3. Silva M, Santos ES, Pedroso CM, Epstein JB, Santos-Silva AR, Kowalski LP. Prevalence of oral diseases in patients under palliative care: a systematic review and meta-analysis. *Support Care Cancer.* 2024;32(9):607. doi:10.1007/s00520-024-08723-9
4. McLuskie A, Bowers M, Bayly J, Yule MS, Maddocks M, Fallon M, et al. Nutritional interventions in randomised clinical trials for people with incurable solid cancer: a systematic review. *Clin Nutr.* 2025;44:201-19. doi:10.1016/j.clnu.2024.12.008
5. Kumar R, Sharma N, Martins B, Pereira L. A medication adherence intelligence loop within pharmacy-EHR interoperability networks. *J Artif Intell Healthc Syst.* 2024;3:21. doi:10.68159/v392507026
6. Shrestha R, Shaw E, Mullen L, Sinclair D, Dewhurst F, Todd A. Outcomes of deprescribing for people with life-limiting conditions: a systematic review. *Palliat Med.* 2026;40(4):490-513. doi:10.1177/02692163261416281
7. Simão D, Barata PC, Alves M, Papoila AL, Oliveira S, Lawlor P. Symptom clusters in patients with advanced cancer: a prospective longitudinal cohort study to examine their stability and prognostic significance. *Oncologist.* 2024;29(1). doi:10.1093/oncolo/oyad211
8. Snyder H. Literature review as a research methodology: an overview and guidelines. *J Bus Res.* 2019;104:333-9. doi:10.1016/j.jbusres.2019.07.039
9. Alves R, Costa B. Preventive care recommendations via benefit-burden trade-offs: a patient-centered utility framework. *J Health Inform Digit Syst.* 2025;5:47. doi:10.68159/k455554631
10. Nakamura H, Kato Y. Predicting severe drug-drug interactions using polypharmacy, pharmacokinetic pathways, and adverse event reports. *Pharmacophore.* 2025;16(2):43-52. doi:10.51847/DPN1uRuBbP
11. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ.* 2021;372. doi:10.1136/bmj.n71
12. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. *BMJ.* 2017;358. doi:10.1136/bmj.j4008
13. Campbell M, McKenzie JE, Sowden A, Katikireddi SV, Brennan SE, Ellis S, et al. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. *BMJ.* 2020;368. doi:10.1136/bmj.l6890
14. Abdurakhmanova AD, Gadjikurbanova ZM, Ashuralova AN, Fedorov IV, Nadzhekh KV, Bargisheva AU, et al. Morphometric parameters of white adipose tissue in rats with a high-fat diet. *Pharmacophore.* 2024;15(3):41-6. doi:10.51847/Pc05ar2YkF
15. Fallon M, Giusti R, Aielli F, Hoskin P, Rolke R, Sharma M, et al. Management of cancer pain in adult patients: ESMO clinical practice guidelines. *Ann Oncol.* 2018;29(Suppl 4). doi:10.1093/annonc/mdy152
16. Jones KF, White GE, Mudumbi S, Eubank AF, Bennett AV, Bulls HW, et al. Characterizing pain and opioid-related risks in individuals with advanced cancer: a cohort study. *J Pain Symptom Manage.* 2026. doi:10.1016/j.jpainsymman.2026.07.031
17. Salem MMI, Abdelaal AAM, El-Fiky AA, Ebid AA, Battecha KH, Thabet AAE, et al. High-intensity laser therapy versus shock wave therapy in the management of diabetic frozen shoulder. *Pharmacophore.* 2024;15(2):113-8. doi:10.51847/twO5acnaXy
18. Sousa MS, Villanueva Garcia M, Blanchard M, Daveson B, Currow D, Khan NN, et al. Navigating pain and appetite challenges in palliative care for pancreatic cancer: insights from a national, longitudinal consecutive cohort study. *Support Care Cancer.* 2025;33(5):365. doi:10.1007/s00520-025-09402-z
19. van der Meulen AI, Stoppelenburg A, Theunissen M, de Nijs EJM, van den Beuken-van Everdingen MHJ, van der Linden YM. Dry mouth in palliative care: a systematic review of clinical practice guidelines around the world. *Palliat Med.* 2026;40(7):933-57. doi:10.1177/02692163261434188
20. Murphy Dourieu E, Lisiecka D, Evans W, Sheahan P. Xerostomia: a silent burden for people receiving palliative care—a qualitative descriptive study. *BMC Palliat Care.* 2025;24(1):1. doi:10.1186/s12904-024-01617-x
21. Serra R, Roque S, Arco H. Oral hygiene care and the management of oral symptoms in patients with cancer in palliative care: a mixed methods systematic review. *JBIC Evid Synth.* 2025;23(8):1565-601. doi:10.11124/JBIES-24-00204
22. Furuya J, Suzuki H, Hidaka R, Matsubara C, Motomatsu Y, Kabasawa Y, et al. Association between oral health and advisability of oral feeding in advanced cancer patients receiving palliative care: a cross-sectional study. *Support Care Cancer.* 2022;30(7):5779-88. doi:10.1007/s00520-022-06984-w
23. Fleming M, Craigs CL, Bennett MI. Palliative care assessment of dry mouth: what matters most to patients with advanced disease? *Support Care Cancer.* 2020;28(3):1121-9. doi:10.1007/s00520-019-04908-9
24. Arakawa S, Amano K, Koshimoto S, Okamura S, Sakaguchi T, Matsuda Y, et al. Assessing the need for multimodal care in anorexia and cachexia patients with advanced cancer referred to palliative care: a

- secondary analysis of a multicenter survey in Japan. *Support Care Cancer*. 2025;33(10):837. doi:10.1007/s00520-025-09889-6
25. Amano K, Okamura S, Matsuda Y, Baracos VE, Mori N, Miura T, et al. Associations of nutrition impact symptoms with depression in patients with advanced cancer. *Support Care Cancer*. 2024;32(7):445. doi:10.1007/s00520-024-08645-6
 26. Amano K, Baracos VE, Hopkinson JB. Integration of palliative, supportive, and nutritional care to alleviate eating-related distress among advanced cancer patients with cachexia and their family members. *Crit Rev Oncol Hematol*. 2019;143:117-23. doi:10.1016/j.critrevonc.2019.08.006
 27. Amano K, Koshimoto S, Sakaguchi T, Tokoro A, Arakawa S, Takeuchi T, et al. Palliative care team involvement is associated with changes in nutrition impact symptoms and eating-related distress in patients with advanced cancer: a multicenter prospective observational study. *Nutrients*. 2026;18(13):2174. doi:10.3390/nu18132174
 28. Lin YC, Turner K, Rajasekhara S, Kim DW, Biachi de Castria T, Nguyen OT, et al. Early supportive and nutritional care for adults with pancreatic cancer: a pilot study. *J Pain Symptom Manage*. 2025;70(5):490-502. doi:10.1016/j.jpainsymman.2025.07.032
 29. Elsten EECM, Pot IE, Geijteman ECT, Hedman C, van der Heide A, van der Kuy PHM, et al. Recommendations for deprescribing of medication in the last phase of life: an international Delphi study. *J Pain Symptom Manage*. 2024;68(5):443-55.e2. doi:10.1016/j.jpainsymman.2024.07.029
 30. Fernández-Fradejas J, Martínez-Barros H, Rexach-Cano L, Álvarez-Díaz AM, Delgado-Silveira E. Deprescribing in older patients with advanced cancer referred to palliative care. *BMJ Support Palliat Care*. 2024;14(e2). doi:10.1136/spcare-2024-004849
 31. Schenker Y, Park SY, Jeong K, Pruskowski J, Kavalieratos D, Resick J, et al. Associations between polypharmacy, symptom burden, and quality of life in patients with advanced, life-limiting illness. *J Gen Intern Med*. 2019;34(4):559-66. doi:10.1007/s11606-019-04837-7
 32. Lowry MF, Lee S, Hoke MF, Leung ER, Roup H, Linge HE, et al. Pharmacist-led opioid deprescribing pilot clinic within outpatient palliative care. *J Pain Symptom Manage*. 2025;70(5). doi:10.1016/j.jpainsymman.2025.07.020
 33. Wong B, Maleki S, Walpole G, Lee YY, Schembri E, Moustafa J, et al. Polypharmacy and deprescribing patterns in an Australian palliative care unit: a cohort study. *J Pain Symptom Manage*. 2026. doi:10.1016/j.jpainsymman.2026.09.009
 34. Choi YY, Hong B, Rha SY, Cho S, Lee HS, Lee J. The effect of nurse-led enhanced supportive care as an early primary palliative care approach for patients with advanced cancer: a randomized controlled trial. *Int J Nurs Stud*. 2025;168:105102. doi:10.1016/j.ijnurstu.2025.105102
 35. Phetlerthirunkul P, Tsianakas V, Ayis S, Harris R. Clinical effectiveness of nurse-led palliative care interventions for patients with advanced cancer: a systematic review and meta-analysis. *Int J Nurs Stud*. 2026;174:105303. doi:10.1016/j.ijnurstu.2025.105303
 36. Dong J, Arulsamy KK, Malhotra C, Finkelstein EA, Ozdemir S. Trajectories of goals of care among patients with advanced cancer in the last two years of life. *J Pain Symptom Manage*. 2026;71(5):659-67. doi:10.1016/j.jpainsymman.2026.01.023
 37. Schenker Y, Althouse AD, Rosenzweig M, White DB, Chu E, Smith KJ, et al. Effect of an oncology nurse-led primary palliative care intervention on patients with advanced cancer: the CONNECT cluster randomized clinical trial. *JAMA Intern Med*. 2021;181(11):1451-60. doi:10.1001/jamainternmed.2021.5185
 38. McAdam C, O'Dwyer E, Dalton K. Pharmacist-led deprescribing interventions for cancer patients in a specialist palliative care setting. *Support Care Cancer*. 2025;33(4):321. doi:10.1007/s00520-025-09341-9
 39. van Merendonk LN, Crul M. Deprescribing in palliative patients with cancer: a concise review of tools and guidelines. *Support Care Cancer*. 2022;30(4):2933-43. doi:10.1007/s00520-021-06605-y